$6.33
0[0.00%]
At close: Apr 24
$6.33
0[0.00%]
PreMarket: 4:00PM EDT
Replimune Group
(NASDAQ:REPL)Latest News for Replimune Group Stock (NASDAQ:REPL)
Replimune Group Stock (NASDAQ: REPL)
Categories: All
Thursday, February 08, 2024
Wednesday, December 06, 2023
Tuesday, December 05, 2023
- Crude Oil Moves Lower; AutoZone Profit Tops ViewsLisa Levin - Dec 5, 2023, 2:27PM
- Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionLisa Levin - Dec 5, 2023, 1:06PM
- 12 Health Care Stocks Moving In Tuesday's Intraday SessionBenzinga Insights - Dec 5, 2023, 12:31PM
- Dow Falls 100 Points; ISM Services PMI Increases In NovemberLisa Levin - Dec 5, 2023, 12:11PM
- US Stocks Down; JM Smucker Posts Upbeat EarningsLisa Levin - Dec 5, 2023, 9:39AM
- Replimmune shares are trading lower after the company announced results from the primary analysis of the CERPASS trial evaluating RP1 in combination with cemiplimab for the treatment of locally advanced or metastatic CSCC and provided initial data for all patients in the anti-PD1 failed melanoma cohort of the IGNYTE clinical trial.Benzinga Newsdesk - Dec 5, 2023, 8:57AM
- What's Going On With Cancer-Focused Replimune Stock Today?Vandana Singh - Dec 5, 2023, 8:49AM
- 12 Health Care Stocks Moving In Tuesday's Pre-Market SessionBenzinga Insights - Dec 5, 2023, 8:07AM
- Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin CancersBenzinga Newsdesk - Dec 5, 2023, 7:01AM
Monday, November 13, 2023
Wednesday, November 08, 2023
- Wedbush Reiterates Outperform on Replimune Group, Maintains $52 Price TargetBenzinga Newsdesk - Nov 8, 2023, 9:14AM
- Replimune Presents Updated Data On RP2 In Uveal Melanoma During Plenary Session At The 20th International Congress Of The Society For Melanoma ResearchBenzinga Newsdesk - Nov 8, 2023, 9:14AM
Tuesday, November 07, 2023
Tuesday, September 19, 2023
Monday, August 07, 2023
Thursday, August 03, 2023
Tuesday, August 01, 2023
Thursday, June 15, 2023
Thursday, June 08, 2023
Wednesday, June 07, 2023
Monday, June 05, 2023
- 12 Health Care Stocks Moving In Monday's Intraday SessionBenzinga Insights - Jun 5, 2023, 1:31PM
- Why Amedisys Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Monday's Mid-Day SessionLisa Levin - Jun 5, 2023, 1:09PM
- Replimune Group shares are trading higher on continued upward momentum after the company presented data from the IGNYTE anti-PD1 failed melanoma cohort and Phase 1 trial of RP2 data in patients with uveal melanoma at the 2023 ASCO annual meeting.Benzinga Newsdesk - Jun 5, 2023, 12:15PM
- Director at Replimune Group Acquires Company Stock Options Worth 50,400 SharesBenzinga Insights - Jun 5, 2023, 11:00AM
- HC Wainwright & Co. Maintains Buy on Replimune Group, Raises Price Target to $51Benzinga Newsdesk - Jun 5, 2023, 6:21AM
- EF Hutton Reiterates Buy on Replimune Group, Maintains $60 Price TargetBenzinga Newsdesk - Jun 5, 2023, 4:07AM
Saturday, June 03, 2023
Friday, May 26, 2023
Monday, May 22, 2023
Thursday, May 18, 2023
Monday, April 17, 2023
Thursday, April 13, 2023
Monday, February 27, 2023
- Replimune Group Says Minor Changes To SAP Were Agreed Unrelated To Dual Independent Primary Endpoints Of Overall Response Rate And Complete Response Rate; Continue To Expect To Make A Biologics License Application Submission For RP1 In Early 2024Happy Mohamed - Feb 27, 2023, 8:58AM
- Replimune Group Says Have Met With FDA To Discuss Response Following Submission In Sept 2022 Of Draft Statistical Analysis Plan For Cerpass Clinical Trial; FDA Agreed No Changes Would Be Made To Clinical Trial Protocol And That No Material Changes Would Be Made To Data Analysis PlanHappy Mohamed - Feb 27, 2023, 8:57AM